Damora Therapeutics, Inc. quarterly report, Q3 FY2025

Business Context and Reporting Period

This summary covers the Form 10-Q for Galecto, Inc. (Note: The request metadata listed "Damora Therapeutics," but the filing text identifies the registrant as Galecto, Inc., trading under symbol GLTO). The report covers the quarterly period ended September 30, 2025. Galecto is a clinical-stage biotechnology company that recently realigned its strategy to focus exclusively on two product candidates: GB3226 (a dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia) and GB1211 (a galectin-3 inhibitor for oncology and liver disease). The company discontinued its previous candidate, GB2064, following a strategic review.

Key Financial Metrics

Metric Q3 2025 (3 Months) Q3 2024 (3 Months) YTD 2025 (9 Months) YTD 2024 (9 Months)
Revenue $0 $0 $0 $0
Net Loss $(3.13) million $(3.88) million $(9.10) million $(14.70) million
Operating Expenses $3.16 million $3.84 million $9.18 million $15.16 million
Cash and Cash Equivalents $7.61 million (as of Sept 30, 2025)
Accumulated Deficit $286.63 million (as of Sept 30, 2025)
Net Cash Used in Operating Activities N/A N/A $(7.29) million $(13.69) million

Note: The company has no product revenue. All figures are in thousands unless otherwise noted.

Material Changes vs. Prior Period

  • Reduced Operating Expenses: Total operating expenses decreased by 17.8% in Q3 2025 compared to Q3 2024, and by 39.5% on a year-to-date basis. This reduction is primarily due to significant decreases in personnel costs and the absence of restructuring costs in the current period (restructuring costs were $0.97 million in YTD 2024 but $0 in YTD 2025).
  • Improved Net Loss: The net loss narrowed to $3.13 million in Q3 2025 from $3.88 million in the prior year quarter, driven by lower general and administrative expenses and reduced stock-based compensation.
  • Cash Burn: Cash and cash equivalents declined from $14.18 million at year-end 2024 to $7.61 million at September 30, 2025, reflecting a net cash outflow of $7.29 million from operating activities over the nine-month period.
  • Strategic Asset Acquisition: In October 2024, the company acquired the BRM-1420 program (renamed GB3226) from Bridge Medicines, shifting its pipeline focus entirely to oncology and liver disease.

Guidance, Outlook, and Risks

  • Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for at least one year from the filing date. Current cash reserves of $7.6 million are projected to be insufficient to fund operations beyond the preclinical development of GB3226 into 2026.
  • Funding Needs: The company explicitly states it requires substantial additional capital to finance clinical development of GB3226 and GB1211. Plans to mitigate liquidity risk include raising capital through equity or convertible debt financings and/or new collaborations, though no assurances are given that such funding will be available.
  • Development Milestones:
    • GB3226: Received FDA feedback in September 2025 consistent with plans to submit an Investigational New Drug (IND) application in Q1 2026. Phase 1 clinical data is expected in 2027.
    • GB1211: Completed dosing in the extension phase of the GALLANT-1 trial in late October 2025. An investigator-initiated Phase 2 trial in melanoma and HNSCC is ongoing.
  • Risks: Key risks include the inability to secure additional financing, potential delisting from Nasdaq, failure of clinical trials, and the impact of global economic instability and geopolitical conflicts on operations and capital markets.

Investor Verification Checklist

  • Liquidity Runway: Verify the specific timeline for cash exhaustion and the status of any active fundraising efforts or bridge financing.
  • Capital Structure: Review the terms of the Series A Non-Voting Convertible Preferred Stock issued to Bridge Medicines and the potential dilution upon conversion.
  • Regulatory Status: Confirm the submission date of the IND application for GB3226 in Q1 2026 and any potential delays.
  • Expense Management: Monitor if the reduction in personnel and G&A expenses impacts the company's ability to execute its accelerated development plans.
  • Collaboration Pipeline: Assess the likelihood of securing a partnership for GB1211 or GB3226 to offset development costs.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.